跳至主要内容
临床试验/TCTR20220404002
TCTR20220404002已完成不适用

Serum level of interleukin-17 in patients with psoriasis

Hamadan University of Medical sciences0 个研究点目标入组 30 人开始时间: 2022年4月4日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
30

研究概览

简要总结

The mean serum levels of IL-17 were significantly higher in patients than in healthy controls. Also, treatment of psoriasis with topical medications reduced serum level of IL-17 and severity of disease, which reflecting the value of IL-17 as a biomarker in assessment of response to treatment.

研究设计

研究类型
Observational

入排标准

年龄范围
28 Years 至 72 Years(—)
性别
All

入选标准

  • Patients with psoriasis referred to dermatology clinic were selected based on definite clinical and pathological criteria. The patients should have active psoriatic skin lesions and a history of disease, without recent use of topical or systemic corticosteroid in the last three months. Healthy subjects (the control group) were selected from non-familial companions referred to the clinic if they had no history of autoimmune or inflammatory diseases.

排除标准

  • Subjects with a history of concomitant autoimmune or inflammatory diseases, as well as pregnant or lactating women were excluded.

研究者

相似试验